[The effect of immunotherapy and hyperthermia on advanced or recurrent ovarian and uterine cancer – 229 clinical cases]

PMID: 25335722
Journal: Gan to kagaku ryoho. Cancer & chemotherapy (volume: 41, issue: 10, Gan To Kagaku Ryoho 2014 Oct;41(10):1295-7)
Published: 2014-10-01

Nakamura K, Hanazawa S, Takeda T, Sumiyoshi R, Kobayashi S, Takeda H, Takeda T


We treated 116 advanced or recurrent ovarian cancer and 102 uterine cancer patients with hyperthermia and/or immunotherapy(2005/7-2013/11). Of these, 63, 31, and 8 patients had cervical cancer, endometrial cancer, and uterine sarcoma, respectively. Standard therapy showed no effect or was refused by these patients. Twenty-nine(25.0%)ovarian cancer patients experienced a clinical benefit(complete response[CR], partial response[PR], and long-term stable disease[SD], >6 months). The effective rate of a combination of therapies including activated lymphocyte therapy, dendritic cell therapy, and hyperthermia was 47.5%. Thirteen(12.7%)uterine cancer patients experienced a clinical benefit. The effective rates for cervical cancer, endometrial cancer, and uterine sarcoma were 7.9%, 22.5%, and 12.5%, respectively. Both hyperthermia and immunotherapy were administered to successfully treat these patients.